Introduction {#S1}
============

Parkinson's disease (PD) is the second leading neurodegenerative disease worldwide. It is caused by a progressive loss of neurons in the substantia nigra, and characterized by clinical features including resting tremor, bradykinesia, rigidity, postural instability and gastrointestinal dysfunction ([@B17]; [@B50]). Although several genetic and environmental factors have been implicated ([@B28]; [@B14]), the etiology of PD is not fully understood.

The imbalance of metals homeostasis in PD has been debated for decades. Iron was more implicated in PD for its property that is easy to generate free radical ([@B47]; [@B73]; [@B29]; [@B60]; [@B4]). Iron selectively accumulation in the substantia nigra, which is acknowledged in PD ([@B15]; [@B75], [@B74]; [@B13], [@B12]; [@B26]; [@B79]), accelerates nigrostriatal neurodegeneration through oxidative stress which was generated by Fenton reaction ([@B73]; [@B60]) and Fe^3+^-melanin complexes formation ([@B84]; [@B25]). Iron elevation is also reported in familial PD, indicating a link between iron accumulation in the substantia nigra and the PD-associated proteins, such as alpha-synuclein, LRRK2, PINK1, Parkin, and DJ-1 ([@B31], [@B30]; [@B71]; [@B7]). Increasing magnetic susceptibility (a surrogate marker of brain iron) in the globus pallidus and red nuclei was associated with decreasing manual dexterity ([@B49]). Unlike changes in the substantia nigra, iron levels were not changed in the cerebellum, caudate nucleus, putamen, and cerebral cortex in postmortem PD brains, as well as reduced in the globus pallidus compared with control values ([@B13]). In addition, in our previous work, iron levels were found decreased in the temporal cortex in PD postmortem brains ([@B85]).

Although the imbalance of cerebral iron metabolism in PD patients is well-documented, the change of iron levels in the peripheral blood and the cerebrospinal fluid (CSF) in PD patients was not fully identified. To date, studies on the alteration of iron levels in blood ([@B8]; [@B53]; [@B37]; [@B19]; [@B32]; [@B24]; [@B1]; [@B20], [@B21]; [@B56]; [@B86]; [@B45]) and CSF ([@B23]; [@B53]; [@B37]; [@B19]; [@B6]; [@B2]; [@B34]) in PD patients reported controversial results. Here, a case-control study plus a quantitative meta-analysis were performed to evaluate the alteration of iron levels in the serum and CSF in PD patients.

Materials and Methods {#S2}
=====================

Case-Control Study {#S2.SS1}
------------------

### Clinical Samples {#S2.SS1.SSS1}

The study protocol was approved by the Institutional Ethics Committee of Medical College of Qingdao University (2016N012), and conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent to participate. Fifty patients with PD (25 female and 25 male) over 40 years were recruited from the affiliated hospital of Qingdao university (Qingdao, Shandong, China) between Jan 2018 and Oct 2018. The PD patients were diagnosed according to the "UK Parkinson's Disease Society Brain Bank Criteria" ([@B63]; [@B86]). The following exclusion criteria were applied to PD patients: (a) Ethanol intake higher than 80 g/day in the last 8 months. (b) Acute infectious disorders, traumatisms or surgery in the last 6 months. (c) Atypical dietary habits. (d) Blood donation histories. (e) Systemic diseases, including anemia, hepatosis, heart failure, pulmonary disorders and chronic renal failure. (f) Female patients who had not been through menopause. (g) PD patients with history of restless leg syndrome (RLS), periodic limb movement disorder (PLMD) and excessive daytime sleepiness (EDS).

For control purpose, 50 healthy persons (25 female and 25 male) over 40 years were included from the physical examination center of the same hospital. All these controls were affirmed with no signs of neurodegenerative disease and without proven organic disease, iron-deficiency anemia, and neurologic or psychiatric disease. After excluding the hemolytic samples, 43 patients with PD (21 female and 22 male) and 33 healthy control (19 female and 14 male) was included. Among them, 15 normal and 12 PD patients donated CSF.

### Collection and Measurement of Sample {#S2.SS1.SSS2}

Blood samples were collected by venipuncture in the morning between 7 and 8 A.M after a night fasting, then centrifuged for serum and rapidly stored at −80°C for further analysis. CSF was collected from patients and controls in the acid-wash tube by lumbar puncture. Prior to analysis, 20 μl serum or CSF were added with 1 mL concentrated HNO~3~ (Yingdong, Jinan, China), and digested in the oven at 55°C overnight. After digestion, samples were diluted (1:50) with ultra pure water to detect the final iron concentration. Iron concentration was measured by inductively coupled plasma atomic emission spectrometry (Agilent Technologies 770 series), which belongs to the Qingdao water quality monitoring center. Argon gas flow rate was maintained at 16 L/min and 1 KW power was used. The standards of iron of 10, 20, 50,100, 200 μg/L were prepared and calibrated. The wavelength of detection was 259.94 nm. Quality control of the analyses was performed by analyzing certified standard reference material. Ferritins, total iron binding capacity (TIBC), transferrin saturation were analyzed in the affiliated hospital of Qingdao university using a KX21 automatic blood cell analyzer (Sysmex, Japan) for routine blood tests.

### Statistic Analyses {#S2.SS1.SSS3}

Statistical analyses were conducted with Stata 15.0 software (Stata Corp., College Station, TX, United States). Means for iron levels, ferritin levels, total iron binding capacity, transferring saturation were compared using two-sample t-test. A p-value less than 0.05 were considered significant in all statistical analyses. As a standardized measure of effect size, we estimated the difference between two group using Cohen's d. All participants in the case-control study were also included in the meta-analysis.

Meta-Analysis {#S2.SS2}
-------------

A systematic literature search from January 1980 to December 2018 was conducted using the PubMed, Web of Science, EMBASE database. The search terms were "Parkinson's disease" OR "Parkinson" OR "PD" combined with "iron" OR "Fe." The reference lists of retrieved articles were also reviewed to identify additional studies not captured by our database search. These articles are managed by Endnote X7 software.

For inclusion, studies had to meet the following criteria: (1) observational studies in humans, (2) original study reported the iron levels in serum, plasma or CSF, (3) sample size and iron levels (Mean ± standard error of mean or Mean ± standard deviations) were provided; (4) Iron levels both of PD patients and healthy control were given. The following exclusion criteria were also used: (1) reviews, editorials, letters without original data mentioned, (2) articles about familial PD, (3) unit of iron levels was not given.

The following data were extracted from each study by two investigators separately: the first author's name, publish year, country in which the study was conducted, sample size, mean age of patients and controls, male's percentage, tested method of iron, diagnostic criteria of PD, mean ± SD levels of iron in serum, plasma or CSF, fasting status, match of potential confounders. If the standard error of mean (SEM) was provided in this study, SEM was converted to standard deviation (SD) by the following formula: ${SD} = {{SEM} \times \sqrt{n}}$.

The standardized mean difference (SMD) with 95% confidence interval (CI) was calculated by using the random effects model to assess the pooled difference on iron levels between PD patients and controls. Heterogeneity among studies was assessed by I^2^ statistical measure ([@B33]). Meta-regression with restricted maximum likelihood estimation was performed to describe the potentially important covariates. In the cumulative meta-analysis, studies were added one at a time in the order of year published, and the results were summarized sequentially. Influence analysis was conducted to investigate whether an individual study affected the pooled result or not. Small-study effect was assessed with funnel plot and Egger test. Sensitivity analysis was conducted by only including studies that excluded subjects with hepatopathy, nephropathy, atypical dietary habits, intake of iron supplements and chelating agents, as well as studies that excluded subjects with blood transfusions, blood donation anemia. All statistical analyses were performed with Stata version 15.0 software (Stata Corporation, College Station, TX, United States).

Results {#S3}
=======

Case-Control Study {#S3.SS1}
------------------

Patients with PD and the controls did not differ for age \[PD, 69.5 ± 5.9; controls, 67.6 ± 4.3; *p* = 0.26\], as well as for sex distribution (χ^2^ = 0.40, *p* = 0.36). As shown in [Table 1](#T1){ref-type="table"}, PD patients had significantly lower ferritin level than controls (*p* = 0.014). Although serum iron, TIBC, and transferrin saturation showed a downward trend in PD patients compared with the controls, these changes did not reach statistical significance. Fifteen control (male/female, 7/8; age, 62.5 ± 4.9) and 12 PD patients (male/female, 5/7; age, 65.3 ± 5.7) donated CSF. CSF levels of iron were lower in PD patients compared with that of controls (*p* = 0.021), with a moderate effect size (Cohen's d: 0.51; 95% CI: 0.43--0.65).

###### 

The level of iron in CSF and iron storage in serum among control and PD groups.

                                        **Control (Mean ± SD)**     **PD patients (Mean ± SD)**   ***P***   **Cohen's d**   **95% CI of Cohen's d**
  ------------------------------------- --------------------------- ----------------------------- --------- --------------- -------------------------
  Serum iron (μg/dL)                    110.00 ± 48.75 (*n* = 43)   107.21 ± 34.25 (*n* = 33)     0.780     0.12            0.08∼0.17
  Ferritin (ng/mL)                      220.81 ± 79.46 (*n* = 43)   176.09 ± 72.42 (*n* = 33)     0.014     0.76            0.62∼0.87
  Total iron binding capacity (μg/dL)   340.51 ± 30.25 (*n* = 43)   336.34 ± 24.36 (*n* = 33)     0.519     0.10            0.06∼0.12
  Transferrin saturation                32.35% (*n* = 43)           31.84% (*n* = 33)             0.210     0.08            0.04∼0.11
  CSF iron (ng/dL)                      20.14 ± 3.35 (*n* = 15)     16.26 ± 4.82 (*n* = 12)       0.021     0.51            0.43∼0.65

Meta-Analysis {#S3.SS2}
-------------

2362 articles were identified by our literature search. 2333 articles were excluded after review of titles or abstracts. 7 studies were excluded after reviewing the full texts of 29 possibly relevant articles ([@B78]; [@B3]; [@B61]; [@B76]; [@B77]; [@B16]; [@B63]). Of them, 3 articles did not provide SD or SEM ([@B78]; [@B3]; [@B77]), 2 were reviews ([@B78]; [@B76]), 1 article was lacking data of iron level ([@B63]), 1 article was lacking of control group ([@B61]). For the remaining 22 articles, 13 of them reported the serum or plasma iron ([@B8]; [@B53]; [@B32]; [@B18]; [@B24]; [@B1]; [@B20], [@B21]; [@B16]; [@B56]; [@B86]; [@B45]; [@B57]), 4 of them reported the CSF iron ([@B23]; [@B6]; [@B2]; [@B34]), and 5 of them reported both serum and CSF iron ([@B37]; [@B19]; [@B66]; [@B35]; [@B70]) ([Table 2](#T2){ref-type="table"}). The steps of the literature search and retrieve are shown in [Figure 1](#F1){ref-type="fig"}.

###### 

Characteristics of included studies in the meta-analysis for iron concentration in blood and CSF.

  **Study**              **Country**   **Unit**   **Parkinson's disease**   **Controls**   **Methods to determine iron levels**   **Food fasting**                                                                                    
  ---------------------- ------------- ---------- ------------------------- -------------- -------------------------------------- ------------------ ----- ------- --------------- ------------------ ------------------------------- -----
  **Studies on serum**                                                                                                                                                                                                                
  [@B8]                  Spain         μg/dL      68                        47.06          65.8 ± 0.96                            82.7 ± 37.33       68    52.94   65.80 ± 1.00    70.9 ± 29.89       --                              yes
  [@B53]                 America       μg/dL      104                       --             --                                     28.3 ± 11.6        352   --      --              33.9 ± 15.2        AAGFM                           --
  [@B37]                 Spain         mg/L       37                        37.84          65.70 ± 8.80                           1.01 ± 0.33        37    43.24   62.40 ± 17.8    0.95 ± 0.3         AAS                             yes
  [@B19]                 Italy         μg/L       26                        92.31          64.90 ± 10.80                          23.54 ± 8.59       13    46.15   63.80 ± 13.70   20.29 ± 7.02       ICP-AES                         yes
  [@B18]                 Italy         ng/mL      71                        74.65          65.50 ± 9.40                           1122 ± 432         44    75.00   51.90 ± 4.00    1596 ± 442         ICP-AES                         --
  [@B32]                 India         μol/mL     27                        51.85          57.15 ± 5.20                           0.02 ± 0.004       25    52.00   55.40 ± 6.40    0.023 ± 0.009      ICP-AES                         --
  [@B66]                 Sweden        mg/L       19                        32.00          72.00 ± 17.00                          1.09 ± 0.45        21    38.09   62.00 ± 11.00   1.16 ± 0.23        AAS                             yes
  [@B24]                 Norway        μg/L       38                        48.48          --                                     1251 ± 551         99    48.48   --              1146 ± 463         ICP-MS                          --
  [@B1]                  India         μg/dL      45                        57.78          57.62 ± 9.10                           110.4 ± 0.6        42    59.52   55.62 ± 3.25    123 ± 8            ICP-AES                         --
  [@B20]                 China         μg/mL      58                        62.00          64.20 ± 9.40                           2 ± 0.83           82    57.31   63.65 ± 9.35    1.5 ± 0.78         ICP-AES                         yes
  [@B56]                 Turkey        μg/dL      60                        55.00          68.50 ± 8.30                           74.6 ± 29.29       42    52.38   66.90 ± 8.30    74.8 ± 27.11       --                              yes
  [@B16]                 Iran          mg/dL      50                        56.00          64.53 ± 10.18                          70.22 ± 25.18      50    50.00   63.53 ± 9.78    67.62 ± 39.53      Biochemical methods             no
  [@B21]                 China         μg/mL      58                        62.00          64.30 ± 9.40                           2.1 ± 0.84         81    58.02   63.70 ± 9.40    1.51 ± 0.78        ICP-AES                         yes
  [@B35]                 China         nmol/mL    102                       46.09          56.31 ± 13.38                          4.12 ± 1.06        31    --      --              4.19 ± 1.05        ELISA                           yes
  [@B57]                 Italy         ug/dL      92                        67.40          70(38--83)                             79 ± 34            112   35.80   62(31--87)      86.1 ± 34.9        American Monitor KDA analyzer   yes
  [@B70]                 India         μg/L       250                       64.80          57.88 ± 12.06                          1156 ± 264.94      280   65.35   56.42 ± 9.68    1205.49 ± 316.09   AAS                             no
  **Studies on plasm**                                                                                                                                                                                                                
  [@B86]                 China         μg/L       238                       50.80          67.10 ± 11.30                          1656 ± 749         153   50.66   67.00 ± 12.10   1470 ± 648         AAS                             yes
  [@B45]                 India         ng/mL      150                       71.33          55.70 ± 10.60                          554.4 ± 123.8      170   70.58   53.73 ± 10.90   421.7 ± 126.1      ICP-AES                         --
  **Studies on CSF**                                                                                                                                                                                                                  
  [@B23]                 Italy         μg/L       11                        90.91          64.9(49--78)                           181 ± 75.1         22    90.90   --              275.9 ± 153.6      AAS                             --
  [@B37]                 Spain         mg/L       37                        37.84          65.70 ± 8.80                           0.17 ± 0.17        37    43.24   62.40 ± 17.80   0.21 ± 0.15        AAS                             yes
  [@B19]                 Italy         μg/L       26                        92.31          64.90 ± 10.80                          33 ± 29.4          13    46.15   63.80 ± 13.70   73.3 ± 72.7        ICP-AES                         yes
  [@B66]                 Sweden        μg/L       19                        68.42          72.00 ± 17.00                          397 ± 217.94       21    38.09   62.00 ± 11.00   237 ± 169.56       AAS                             yes
  [@B6]                  Italy         ng/mL      91                        70.33          65.50 ± 9.70                           28.2 ± 14.6        18    55.56   63.30 ± 13.80   45 ± 30.2          ICP-AES                         yes
  [@B2]                  Italy         μg/L       42                        85.71          64.50 ± 10.70                          28.2 ± 14.6        20    85.00   66.20 ± 14.70   35.5 ± 5.03        ICP-AES                         yes
  [@B34]                 Japan         μg/L       20                        45.00          68.7 ± 5.8                             263.9 ± 112.9      15    40.00   48.2 ± 22.2     238 ± 54.7         ICP-MS                          --
  [@B35]                 China         nmol/mL    51                        45.10          61.23 ± 13.18                          0.458 ± 0.197      31    --      --              0.495 ± 0.173      ELISA                           yes
  [@B70]                 China         μg/L       50                        70.00          58.72 ± 12.83                          182.88 ± 89.28     60    70.00   60.11 ± 10.44   212.46 ± 33.58     AAS                             no

AAS, Atomic absorption spectrophotometer; AAGFM, Atomic absorption graphite furnace micromethod; ELISA, Enzyme linked immunosorbent assay; ICP-AES, Inductively coupled plasma atomic emission spectrometry; ICP-MS, Inductive coupled plasma mass spectroscopy.

![Flow of the literature.](fnins-13-00939-g001){#F1}

### Iron Concentration Does Not Differ in Blood in Parkinson's Disease {#S3.SS2.SSS1}

Besides our study, 18 studies on serum or plasma level of iron were included in this meta-analysis (16 in serum, 2 in plasma). Heterogeneous results were observed in these studies: 3 studies reported an increase of iron levels in PD patients compared with that in controls ([@B20], [@B21]; [@B45]), 6 studies reported a decrease ([@B53]; [@B32]; [@B18]; [@B86]; [@B57]; [@B70]), and 9 reported no difference ([@B8]; [@B37]; [@B19]; [@B66]; [@B24]; [@B1]; [@B16]; [@B56]; [@B35]). Including the subjects recruited in our study, 1555 PD cases and 1889 controls was involved. As shown in [Figure 2A](#F2){ref-type="fig"}, no significant difference was found in serum or plasma levels of iron between PD patients and controls in this meta-analysis. The pooled SMD from random-effects model was −0.03 (95% CI: −0.30, 0.24; *I*^2^ = 92.5%). High heterogeneity (*I*^2^ = 92.5%, *P* \< 0.001) was found in the analysis.

![Association between blood levels of iron and Parkinson's disease. **(A)** Forest plot of the Parkinson's disease risk for blood iron level. **(B)** Cumulative meta-analysis of the Parkinson's disease risk for blood iron level. The standardized mean difference (SMD) with 95% confidence interval (CI) was calculated by using the random effects model.](fnins-13-00939-g002){#F2}

In order to explore the source of the between-study heterogeneity, subgroup analysis and meta-regression was conducted. As summarized in [Table 3](#T3){ref-type="table"}, no significant statistically difference was found in subgroup analysis by covariates of continent (the study was from Asia, Europe, America, Africa, Oceania), detection method of iron (ICP-AES, AAS, other), and sample type (serum, plasma). However, a higher blood iron level was found in studies assessing iron levels with subjects in fasting status \[SMD (95% CI): 0.208 (0.019, 0.397)\], but not in studies with subjects in non-fasting status \[SMD (95% CI): −0.346 (-0.907, 0.216)\]. Univariate meta-regression suggested no covariate was responsible for between-study heterogeneity. *P* values of covariates of continent, food fasting, sample type, and tested methods of iron level were 0.68, 0.09, 0.14, and 0.78, respectively.

###### 

Subgroup analysis of iron level in blood and Parkinson's disease.

  **Subgroup**                    **Numbers of studies**   **SMD (95% CI)**       **Test of SMD = 0**   **Heterogeneity**            
  ------------------------------- ------------------------ ---------------------- --------------------- ------------------- -------- -----------
  **Continent**                                                                                                                      
  Asia                            11                       0.019(−0.362,0.399)    0.10                  0.924               0.00%    0.000^∗∗^
  Europe                          7                        −0.052(−0.446,0.342)   0.26                  0.797               84.00%   0.000^∗∗^
  **Food fasting**                                                                                                                   
  Yes                             10                       0.208(0.019,0.397)     2.16                  0.031               67.00%   0.001^∗^
  No                              8                        −0.346(−0.907,0.216)   1.21                  0.227               96.40%   0.000^∗∗^
  **Detection methods of iron**                                                                                                      
  ICP-AES                         7                        −0.103(−0.826,0.620)   0.28                  0.780               96.30%   0.000^∗∗^
  AAS                             4                        0.042(−0.255,0.339)    0.28                  0.782               78.00%   0.003^∗^
  Other                           7                        −0.018(−0.237,0.201)   0.16                  0.873               66.90%   0.006^∗^
  **Sample**                                                                                                                         
  Serum                           16                       −0.124(−0.403,0.154)   0.88                  0.381               90.1%    0.000^∗∗^
  Plasma                          2                        0.477(−0.129,1.082)    1.54                  0.123               94.0%    0.001^∗^

SMD, standardized mean difference; CI, confidence interval;

∗∗

P

\< 0.001,

∗

P

\< 0.01 were considered significant.

Egger's test (*p* = 0.23) showed that no evidence of publication bias was found. In influence analyses, there was no significant change in the 95% CI after excluding any of the studies. This means no individual study had an excessive influence on the pooled effect. In cumulative meta-analysis showed in [Figure 2B](#F2){ref-type="fig"}, blood levels of iron did not differ significant between PD patients and controls after including one paper in 1997. In sensitivity analysis, the pooled SMD were −0.14 (95% CI: −0.55--0.26, *I*^2^ = 85.5%, *P* = 0.000) for studies that excluded subjects with hepatopathy, nephropathy, atypical dietary habits, intake of iron supplements and chelating agents, as well as −0.02 (95% CI: −0.28--0.24, *I*^2^ = 55%, *P* = 0.084) for studies that excluded subjects with blood transfusions experience, blood donation anemia.

### Iron Concentration Tends to Be Lower in CSF in Parkinson's Disease {#S3.SS2.SSS2}

Nine studies on CSF levels of iron between patients with PD and controls were involved in this meta-analysis ([@B23]; [@B53]; [@B37]; [@B19]; [@B6]; [@B66]; [@B2]; [@B34]; [@B70]), as well as 347 PD patients and 237 controls were involved. Among them, 2 study found an increase of iron levels ([@B53]; [@B34]), 2 found a decrease ([@B2]; [@B70]), and 5 found no difference between PD patients and controls ([@B23]; [@B37]; [@B19]; [@B6]; [@B66]). The pooled result showed that CSF levels of iron tend to be lower in PD patients compared with that in the controls ([Figure 3](#F3){ref-type="fig"}). The pooled SMD from random effects model was −0.33 \[95% CI:(−0.65, 0.00), *I*^2^ = 68.4%, *P* for *I*^2^ = 0.001\]. Univariate meta-regression showed no covariate having impact on between-study heterogeneity, *p* values of covariates continent, food fasting, iron test methods were 0.53, 0.07 and 0.31 respectively. Egger's test (*p* = 0.710) and visual inspection of the Egger's funnel plot showed no evidence of small-study effects for all included studies.

![Forest plot of the Parkinson's disease risk for cerebrospinal fluid level of iron. The standardized mean difference (SMD) with 95% confidence interval (CI) was calculated by using the random effects model.](fnins-13-00939-g003){#F3}

Discussion {#S4}
==========

The alteration of iron homeostasis in PD has been debated for decades. It has been accepted that iron accumulation in the substantia nigra in PD patients, but the alteration of iron levels in blood and CSF is not fully recognized. In the case-control study conducted by us, no significant difference was found in serum levels of iron between patients and controls. In the meta-analysis, no significant difference was found in blood levels of iron between patients and controls, and the cumulative meta-analysis found no difference after including one paper in 1997. The polled SMD did not change substantially in subgroup analyzes and sensitivity analyzes, except that a higher blood iron level was found in studies with subjects in fasting status. Meanwhile, iron levels in CSF tend to be lower in PD patients than in the controls both in the case-control study and the meta-analysis.

Abnormal deposition of iron in PD brains was first reported in 1924 ([@B48]). The underlying mechanism for iron deposits in the substantia nigra remains unknown. It is still in debated that the alteration of cerebral iron homeostasis is the cause or the consequence of PD. Several epidemiological studies revealed that occupational exposure to iron or high intake of iron increased the risk for PD ([@B69]; [@B27]; [@B64]). Prospective study showed that dietary non-heme iron intake from food was associated with a 30% increased risk for PD ([@B52]). A low intake of cholesterol in combination with high iron intake increased the risk of developing PD ([@B65]). Experiment conducted in mouse found that iron-overloaded models developed degeneration of dopaminergic neurons, and iron chelation prevented degeneration of midbrain dopaminergic neurons ([@B41], [@B40]; [@B11]). In clinical trials, iron chelation therapy for PD has shown significant improvement ([@B81]). All above evidence supports the hypothesis that iron is involved in the etiology of PD. However, several studies support the role of brain iron accumulation might be independent on the environmental exposure in the development of PD ([@B68]). Some studies failed to demonstrated the risk of iron exposure for PD ([@B83]), even showed that higher intake of iron might be protective against PD ([@B59]). Non-significant difference in iron content has been found in brain tissues showing moderate neurodegeneration ([@B67]), thus, it also could be considered that iron accumulation in PD might be the consequence of neuronal death since otherwise its levels should be increased since the early stages of the disorder. In this meta-analysis, we identified blood levels of iron did not differ significant between PD patients and controls. To some extend, this is in accordance with the hypothesis that brain iron accumulation may be independent on the environmental iron exposure in the development of PD.

In the present study, systemic serum iron metabolism was also measured. Lower ferritin level was observed in PD patients than controls, but no statistical significance was found in serum iron, TIBC, and transferrin saturation between them. Some studies reported that there is no association between iron metabolism and PD, for example, blood donations, which can decrease systemic iron stores, do not lower the risk of PD ([@B51]). However, a study of 213 PD patients and 219 healthy controls reported that ferritin, TIBC, and serum iron decreased gradually with the severity of the disease ([@B10]). The reasons for this variability in iron metabolism in PD patients may because that PD was a highly heterogeneous disease. This heterogeneity can manifest in many different ways, such as sex-specific differences, different genetic backgrounds, the course of disease, disease phenotype. For example, it has been reported that plasma transferrin level correlates with the tremor-dominant phenotype of Parkinson's disease ([@B72]), as well as the abnormally low iron in PD patients was especially pronounced for subjects of haptoglobin Hp 2-1 phenotype, which also have higher risk of PD ([@B9]).

Both in the case-control study and the meta-analysis, iron levels in CSF tend to be lower in PD patients than in the controls. We hypothesized that iron deposition in PD patients in the basal ganglia, especially in the substantia nigra (SN), might lead to the decline of CSF iron levels. Several evidence have showed that elevated iron levels are key events leading to dopaminergic neuron degeneration in PD ([@B42]; [@B39]; [@B82]). Increased iron levels were first observed in neuromelanin (NM)-containing neurons of the substantia nigra pars compacta (SNpc) in patients with PD, indicating that an iron-melanin interaction contributed to dopaminergic neurodegeneration in PD ([@B13]; [@B5]). Although the underlying mechanisms of iron accumulation in the SN are not fully clarified, it seemed resulted from a combination of increased iron import and decreased iron export. It was well known that two pathways were responsible for cellular iron uptake, the transferring (Tf)-transferrin receptor (TfR) pathway, and the non-transferrin-bound iron (NTBI) transport pathway. Tf-TfR is considered the major pathway, as well as the main NTBI pathway was divalent metal transporter 1 (DMT1), which was responsible for ferrous iron uptake. Several other metal transport systems such as the ferritin receptor, lactoferrin/lactoferrin receptor, and melanotransferrin are also involved in the NTBI pathway ([@B54]; [@B44]; [@B55]). Ferroportin is the only known iron transporter responsible for cellular iron export to date ([@B22]), which was first found to transport Fe^2+^ across the basolateral membrane of enterocytes with the auxiliary ferroxidase activity of ceruloplasmin or hephaestin ([@B58]; [@B46]). Amyloid precursor protein (APP) was shown to accelerate iron export from dopaminergic neurons by stabilizing ferroportin. In the substantia nigra of PD models, down-regulated of iron export protein Fpn1 and up-regulated of iron import protein DMT1 and TfR1 were observed, which played critical role in the iron accumulation in the substantia nigra ([@B38]; [@B80]; [@B36]). Neuromelanin also played an important role in the pathogenesis of Parkinson's disease with high binding capacity for iron. The formation of reactive oxygen species through the Fenton reaction catalyzed by neuromelanin-bound iron ions subsequently lead to death of the dopaminergic cells in the substantia nigra ([@B43]).

A main advantage of this study is abundant participants involved in the meta-analysis, making a more possibility to get reliable conclusions. Second, the pooled effects on all studies were consistent with most of the subgroup analysis and sensitive analysis. Third, little evidence of publication bias was detected in this meta-analysis, which indicated that our results were not affected by small-study effects. The limitations in this study should also be mentioned. First, high between-study heterogeneity was detected in the meta-analysis. The stratified analyses and meta-regression analysis did not find any of the following covariate, continents, fasting, sample type, and tested methods of iron as the important contributor to the between-study heterogeneity. Although before-mentioned covariates were not found to be the source of between-study heterogeneity, other possible related covariate, such as iron supplement usage, PD stage, PD complication, testing protocol of sample, etc., could not be excluded. Second, subgroup analysis was not performed on CSF iron levels because studies on CSF were not abundant. Third, the collection, storage and treatment condition of sample were diverse in different studies, which hint us to interpret the results with caution. Finally, the insufficient information provided by the included studies precluded the possibility of sensitive analysis in terms of disease status, phenotype, duration, and PD stage.

In summary, our study indicated blood levels of iron did not differ significant between PD patients and controls, but CSF levels of iron tended to be lower in PD patients compared with that in the controls. Further prospective studies are desired to clarify whether a causal link was existed between iron and PD.
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